The invention relates to a compound of formula (I) wherein R2 and R4 are joined and together form a group, such a —CH2O—. The compound of formula (I) can be used in the manufacture of 5′S-LNA oligonucleotides as antisense drugs. ##STR00001##

Provided is a compound of the general formula (I):

##STR00001##

The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

Provided is a compound of the general formula (I):

##STR00001##

The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

A method for extracting a wasabi extract is characterized in that: 53 to 61 part by weight of a wasabi powder and 25 to 30 parts by weight of pure scotch whisky are mixed to produce a wasabi extract; and the wasabi extract is placed in an oak barrel and fermented for at least 48 hours, after which 14 to 17 parts by weight of a wasabi sinigrin extract that has collected in an upper layer portion is extracted therefrom. Further, when fermenting the wasabi extract to which undiluted whisky has been added inside the oak barrel, wasabi inside yeast cell walls formed in the upper layer portion is collected, and the method has the effect of maintaining the taste and aroma of the wasabi extract collected inside the yeast cell walls, that is, the sinigrin extract.

A method for extracting a wasabi extract is characterized in that: 53 to 61 part by weight of a wasabi powder and 25 to 30 parts by weight of pure scotch whisky are mixed to produce a wasabi extract; and the wasabi extract is placed in an oak barrel and fermented for at least 48 hours, after which 14 to 17 parts by weight of a wasabi sinigrin extract that has collected in an upper layer portion is extracted therefrom. Further, when fermenting the wasabi extract to which undiluted whisky has been added inside the oak barrel, wasabi inside yeast cell walls formed in the upper layer portion is collected, and the method has the effect of maintaining the taste and aroma of the wasabi extract collected inside the yeast cell walls, that is, the sinigrin extract.

The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

The present disclosure discloses a method for preparation of derivatives of gram-positive bacteria surface capsular polysaccharide, and belongs to the field of carbohydrate chemistry. The present disclosure takes glucose as a glycosyl donor to obtain a target -glucosidic bond, then successfully synthesizes a disaccharide building block through a method of redox of a glucose C-2 site, and then takes the disaccharide building block as a repeat unit to synthesize a target oligosaccharide structure such as a derivative [.fwdarw.3)--D-Manp-(1.fwdarw.4)--D-Rhap-(1.fwdarw.].sub.5-Linker of gram-positive bacteria cell wall capsular polysaccharide. A reduction end of decose is linked with a linker to be linked with a protein to make glycoconjugates for immunological studies. The method provided by the present disclosure is simple, time-saving, labor-saving and low-cost, and the resultant derivatives of the gram-positive bacteria surface capsular polysaccharide may be used for development and preparation of medicine related to autism.